SpotitEarly Enters U.S. Market with $20.3M for AI & Canine-Powered Cancer Test SpotitEarly, a biotech company pioneering a non-invasive approach to early cancer detection, has officially launched its U.S. operations following a $20.3 million funding round. The company aims to revolutionize cancer screening through its breath-based diagnostic platform, which integrates advanced AI with canine scent detection to identify cancer-associated volatile organic compounds (VOCs) with 94% accuracy, as demonstrated in a 1,400-participant trial published in Nature’s Scientific Reports. Commercial availability in the U.S. is expected in 2026.